tracken
Mirum Pharmaceuticals Inc Aktie News
TORONTO--(BUSINESS WIRE)--Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Alagille Syndrome.
TORONTO--(BUSINESS WIRE)--Health Canada Authorizes Mirum's LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.
Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year.
Mirum Pharmaceuticals is at an inflection point. The company's sales are growing fast, led by the success of Livmarli.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease.
Mirum Pharmaceuticals, Inc. (MIRM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Meta Platforms is an advertising juggernaut with tremendous growth potential in the AI glasses market. Micron Technology is a steal of a deal among AI stocks.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
